Skip to content
HeyJared

Anna K. Abram

Reporter · US

Indexed articles, last 90 days
3
Latest publication
Aug 27, 2026
Outlet visibility, for Mondaq
Top 500K sites
Earliest in this view
Aug 10, 2026
The latest indexed work is over 30 days old. There may be a gap in what we hold.

Latest articles

  1. Article · Aug 27, 2026 · Anna K. Abram

    PDUFA VIII Pushes Forward: Proposed Commitment Letter Outlines Updates To Drug Review Process (opens the original)

    Excerpt · English

    Read excerpt

    Earlier this month, the U.S. Food and Drug Administration (FDA) released the proposed Prescription Drug User Fee Act (PDUFA) VIII commitment letter marking a pivotal milestone on the path to the seventh reauthorization of the agency’s program authorizing FDA to collect user fees to supplement the costs for the review of human drug applications. PDUFA VIII would span fiscal years 2028 through 2032, as the current authorization (PDUFA VII) is set to expire at the end of Fiscal Year 2027 (September

  2. Article · Aug 12, 2026 · Anna K. Abram

    FDA Seeks Feedback On Proposed Quantitative Medicine Innovation Network (opens the original)

    Excerpt · English

    Read excerpt

    The Food and Drug Administration (FDA) continued its efforts to modernize drug development and regulation with the recent publication of a notice in the Federal Register from the Center for Drug Evaluation and Research’s (CDER) Quantitative Medicine Center of Excellence announcing a request for information (RFI) to inform the development of the Quantitative Medicine Innovation Network (QMIN). The agency is seeking to better understand current quantitative medicine capabilities, challenges, and o

  3. Article · Aug 10, 2026 · Anna K. Abram

    Congress Takes Action On FDA Bills Ahead Of August Recess (opens the original)

    Excerpt · English

    Read excerpt

    The months and weeks leading up to August recess saw an uptick in activity by Congress on Health Care Legislation, including a focus on various aspects of Food and Drug Administration (FDA) policy. As part of this bipartisan, bicameral activity, both the House and Senate advanced FDA-related bills through various stages of the legislative process. There was a recurring focus on streamlining the path to approval for generic drugs and biosimilar products, as well as expediting the development and

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 500K sites

For Mondaq, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Anna K. Abram